HK Stock Market Move | ABBISKO-B(02256) rose more than 5%, it is jointly promoting a new type of targeted immunotherapy for the treatment of NSCLC with AstraZeneca.

ABBISKO-B (02256) rose more than 5% in the morning, up 5.49% as of the time of publication, at HK$11.33, with a turnover of HK$17.3845 million. On the news front, on July 2, ABBISKO-B announced that its subsidiary Shanghai Heyu Biological Pharmaceutical Technology Co., Ltd. (Heyu Pharmaceutical) signed a strategic cooperation agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly promote a new targeted immunotherapy for the treatment of non-small cell lung cancer (NSCLC). The joint study is a multicenter, open-label Phase I/II clinical trial aimed at evaluating the safety and efficacy of Heyu Pharmaceutical's proprietary first-in-class oral small molecule PD-L1 inhibitor ABSK043 (lumipodlin) in combination with AstraZeneca's third-generation EGFR-TKI Tagrisso (osimertinib) for the treatment of locally advanced or metastatic NSCLC patients with EGFR mutations and PD-L1 positive. The new drug clinical trial application (IND) was approved by the National Medical Products Administration (NMPA) on May 20, 2026. The Phase II study will be led by Heyu Pharmaceutical, and both Heyu Pharmaceutical and AstraZeneca will jointly bear the responsibilities of this clinical trial.